

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (original) A transgenic *Xenopus* comprising a gene that is specifically expressed in the lymphatic vessel system of said *Xenopus*.
2. (original) A transgenic *Xenopus* according to claim 1 wherein said gene encodes for a reporter gene or a biologically relevant transgene.
3. (currently amended) A method to produce a transgenic *Xenopus* according to ~~claims~~ 1-2 claim 1 comprising introducing a vector comprising a gene under control of a promoter specifically expressed in the lymphatic vascular system into cells of *Xenopus*.
4. (original) A method according to claim 3 wherein said promoter is selected from the list comprising Podoplanin promoter, Prox-1 promoter, VEGFR-3 promoter and LYVE-1 promoter.
5. (original) A method for visualizing the lymphatic vessel system in *Xenopus* comprising generating a transgenic *Xenopus* comprising a reporter gene that is specifically expressed in the lymphatic vessel system.

6. (currently amended) Use of a transgenic *Xenopus* according to ~~claims 1-2~~ claim 1 to identify a compound capable of modulating lymphatic vessel development comprising:

- a) contacting said transgenic *Xenopus* with a test compound,
- b) comparing the lymphatic vessel system in said transgenic *Xenopus* contacted with said test compound with the lymphatic vessel system of a transgenic *Xenopus* that was not contacted with said test compound and,
- c) determining the effect of said test compound on lymphatic vessel development, such that if lymphatic vessel development in the transgenic *Xenopus* contacted with said test compound is different from the lymphatic vessel development in the transgenic *Xenopus* that was not contacted with said test compound, said compound is a modulator of the lymphatic vessel system.